{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angio-oedema-anaphylaxis/prescribing-information/non-sedating-antihistamines-no-airway-involvement/","result":{"pageContext":{"chapter":{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)","depth":2,"htmlHeader":"<!-- begin field a25fdda4-5919-4f58-b632-4cefb355b2f3 --><h2>Non-sedating antihistamines when there is no airway involvement</h2><!-- end field a25fdda4-5919-4f58-b632-4cefb355b2f3 -->","summary":"","htmlStringContent":"<!-- begin item 6f9ae2a7-5ac3-448a-afc9-059db3612997 --><!-- end item 6f9ae2a7-5ac3-448a-afc9-059db3612997 -->","topic":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558","topicId":"41b219ac-b62a-42d3-9d76-7b3897b21bdd","topicName":"Angio-oedema and anaphylaxis","slug":"angio-oedema-anaphylaxis","lastRevised":"Last revised in November 2018","chapters":[{"id":"f7de7576-f193-57e1-8566-52f77c198d07","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"137d41e2-195c-5b6c-a42b-a2e7774ab4c5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes"},{"id":"0124664c-1848-504a-b629-b001f3d627e7","slug":"update","fullItemName":"Update"}]},{"id":"fd3fe5d3-198d-5e2e-afaa-1de509ee14b0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c36d3c5-8fc2-58ba-91d9-2d00dbb17605","slug":"goals","fullItemName":"Goals"},{"id":"dbfbfeb0-8ad4-5a3d-8458-06af672eab12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bbc732dc-6fbc-5902-a5bf-890776f1df44","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"49ccfcd1-6054-5eac-b6a2-c85eb605ecfd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c97855a-e489-54e6-8f4b-28dbc050951e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71eafab9-7c66-5e57-aa08-197ad09eb9e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed1b7bb1-0232-5ceb-991c-c936ac2a3086","slug":"definition","fullItemName":"Definition"},{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7ebee135-258e-58ce-a91e-947b8a2f9563","slug":"complications","fullItemName":"Complications"},{"id":"7c2a6ca1-0f6a-5a40-bc06-dbbbf95c57c1","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4b20303c-5905-594a-a8c6-4f85e46cf3f9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"005b06b8-18c4-569f-b1b3-3c6d1218ddf7","slug":"diagnosis-of-angio-oedema","fullItemName":"Diagnosis of angio-oedema"},{"id":"682e56cf-4c4d-5736-8db7-4cd4bfcab6e2","slug":"assessing-the-cause-of-angio-oedema","fullItemName":"Assessing the cause of angio-oedema"},{"id":"bf860a63-b9a4-5c14-bf1b-46423d3df7ad","slug":"diagnosis-of-anaphylaxis","fullItemName":"Diagnosis of anaphylaxis"},{"id":"fab5c932-e15e-5303-99e9-48f7d2e415b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis"},{"id":"5759117d-4bde-53b6-b78d-7885ccbf431e","slug":"anaphylaxis-with-or-without-angio-oedema","fullItemName":"Scenario: Anaphylaxis with or without angio-oedema"}]},{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b59ab8fd-de1f-555e-946a-c3a53b918da4","slug":"emergency-drug-doses","fullItemName":"Emergency drug doses"},{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)"},{"id":"dac089ca-3b63-536d-9737-82806f78b88e","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"7ead2f48-36a4-5547-8570-4d4ab5898a73","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a7653e34-460d-5737-b0c3-264ecc26dc68","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a713ee82-3188-50ea-a2bc-a562abd97621","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7421fd02-2e34-5526-bd39-905aa772f800","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d24df800-eddc-5bf3-bea0-d556b5e01aed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"af27ed5c-0853-5d16-91a4-5e5878ee9209","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7640a76-8bc4-569e-8b82-717e6bd5f041","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4778aa1-f37d-574f-8514-47ac86bf2c2e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"91e71f7c-a67b-53f1-9fec-2d53f24d5ee7","slug":"choice-of-antihistamine","fullItemName":"Choice of antihistamine","depth":3,"htmlHeader":"<!-- begin field f8cd24a1-67b5-412a-a6d2-a77c00c7ce51 --><h3>Which non-sedating anti-histamine should I offer?</h3><!-- end field f8cd24a1-67b5-412a-a6d2-a77c00c7ce51 -->","summary":"","htmlStringContent":"<!-- begin item fa0b1c61-5868-47e6-ba10-a77c00c7cd13 --><!-- begin field f787d007-e36e-4fae-880b-a77c00c7ce51 --><ul><li><strong>For most adults, </strong>cetirizine, loratadine, and fexofenadine are usual choices as their long-term safety has been well established and their once-daily dosage may improve adherence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>]. However, any suitable non-sedating antihistamine can be considered as there is no strong evidence that one is more effective than the other [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Sharma, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>].</li><li><strong>In children,</strong> cetirizine, loratadine, or fexofenadine are usual choices and have been well studied [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Fitzsimons, 2015</a>]. <ul><li>The choice of antihistamine should depend on the age of the child (<a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/prescribing-information/non-sedating-antihistamines-no-airway-involvement/#licensed-doses\">licensed ages</a> differ), availabilities (as not all are available in syrup form), and preference (for example what has worked in the past).</li><li>The British National Formulary for Children (BNFC) states that desloratadine or levocetirizine should be reserved for children who cannot tolerate other treatments, because they do not confer any additional benefit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF for Children, 2017</a>].</li></ul></li><li><strong>During pregnancy, </strong>oral antihistamines should be avoided where possible, especially during the first trimester. However, if a non-sedating antihistamine is required, loratadine is recommended as there is considerable clinical experience with its use in pregnancy, with no increase in the rate of congenital abnormalities [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>]. Cetirizine, desloratadine (an active metabolite of loratadine), or levocetirizine (an isomer of cetirizine) may also be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Zuberbier, 2014</a>].<ul><li>Most manufacturers of antihistamines advise avoiding their use during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 72, 2016</a>]; however, there is no evidence of teratogenicity with their use.</li><li>A systematic review and meta-analysis on the risk of adverse pregnancy outcome after first trimester exposure to H1-antihistamines<strong> </strong>found that they do not appear to be associated with an increased risk of major malformation or other adverse fetal outcomes (spontaneous abortions, prematurity, stillbirth, and low birth weight) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Etwel, 2017</a>].</li></ul></li><li><strong>During breastfeeding,</strong> loratadine and cetirizine are recommended. The lowest effective dose for the shortest period of time should be prescribed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>].<ul><li>Most manufacturers of antihistamines advise avoiding their use during breastfeeding as most antihistamines are present in breast milk (in varying amounts) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 72, 2016</a>].</li><li>However, LactMed (a US drugs and lactation database) states that:<ul><li>Loratadine would not be expected to cause any adverse effects in breastfed infants due to its lack of sedation and low milk levels, but it might have a negative effect on lactation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">LactMed, 2013</a>]. </li><li>Cetirizine is probably acceptable during breastfeeding if given in small, occasional doses. However, larger doses or more prolonged use may cause drowsiness and other effects in the infant, or decrease the milk supply particularly before lactation is well established [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">LactMed, 2016</a>]. </li></ul></li></ul></li></ul><!-- end field f787d007-e36e-4fae-880b-a77c00c7ce51 --><!-- end item fa0b1c61-5868-47e6-ba10-a77c00c7cd13 -->","subChapters":[]},{"id":"81d87f1a-319a-501f-8092-cbe742734eca","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 6e346b75-7373-4ca7-84e6-a77c00c7febc --><h3>What are the contraindications and cautions?</h3><!-- end field 6e346b75-7373-4ca7-84e6-a77c00c7febc -->","summary":"","htmlStringContent":"<!-- begin item c1cc705b-1565-4f42-b465-a77c00c7fd8a --><!-- begin field d9c4ff55-f02c-420b-b926-a77c00c7febc --><ul><li><strong>Do not prescribe:</strong><ul><li><strong>Cetirizine to people with:</strong><ul><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 10 mL/minute/1.73 m<sup>2)</sup>.</li><li>Acute porphyria.</li></ul></li></ul></li></ul><ul><li><strong>Prescribe:</strong><ul><li><strong>Cetirizine with caution to </strong><strong>people with</strong> renal impairment.<ul><li>If eGFR is 30–50 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/prescribing-information/non-sedating-antihistamines-no-airway-involvement/#licensed-doses\">dose</a>.</li><li>If eGFR is 10–30 mL/minute/1.73 m<sup>2</sup>, use half normal dose and reduce dose frequency to alternate days.</li></ul></li><li><strong>Loratadine with caution to people with</strong> hepatic impairment.<ul><li>Reduce dose frequency to alternate days in severe impairment.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>]</p><!-- end field d9c4ff55-f02c-420b-b926-a77c00c7febc --><!-- end item c1cc705b-1565-4f42-b465-a77c00c7fd8a -->","subChapters":[]},{"id":"8e77129d-3add-5807-9420-d36c5a304374","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field 92ba2348-1854-47f2-a5db-a77c00fcf97c --><h3>What are the licensed doses?</h3><!-- end field 92ba2348-1854-47f2-a5db-a77c00fcf97c -->","summary":"","htmlStringContent":"<!-- begin item 7e00fbf3-2645-47b7-936f-a77c00fcf7f8 --><!-- begin field afe21910-1f77-4b91-807a-a77c00fcf97c --><ul><li><strong>Antihistamines are not specifically licensed for the treatment of angio-oedema. However, for the treatment of urticaria:</strong><ul><li><strong>The licensed oral doses of cetirizine are:</strong><ul><li>Children aged 2 years to 5 years — 2.5 mg twice daily.<ul><li>Cetirizine is not licensed for use in children aged under 2 years, but the British National Formulary for Children (BNFC) recommends an unlicensed dose of 250 micrograms/kg twice daily for children aged 1 year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF for Children, 2017</a>]. </li></ul></li><li>Children aged 6 years to 11 years — 5 mg twice daily.</li><li>Adults and children aged 12 years and over — 10 mg once daily.</li></ul></li><li><strong>The licensed oral doses of loratadine ar</strong><strong>e:</strong><ul><li>Children aged 2 years to 11 years and body weight up to 31 kg — 5 mg once a day.</li><li>Children age 2 years to 11 years and body weight 31 kg and over —10 mg once a day.</li><li>Adults and children aged 12 years and over — 10 mg once a day.</li></ul></li><li><strong>The licensed oral dose of fexofenadine is</strong><strong>:</strong><ul><li>Adults and children aged 12 years and over — 180 mg once a day.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF for Children, 2017</a>]</p><!-- end field afe21910-1f77-4b91-807a-a77c00fcf97c --><!-- end item 7e00fbf3-2645-47b7-936f-a77c00fcf7f8 -->","subChapters":[]},{"id":"698eb254-cba9-576e-95c9-68a58cd3b3df","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d2bdbbf6-3128-4581-9501-a77c00fd195e --><h3>What are the possible adverse effects?  </h3><!-- end field d2bdbbf6-3128-4581-9501-a77c00fd195e -->","summary":"","htmlStringContent":"<!-- begin item bb738227-a078-4184-aa3e-a77c00fd181a --><!-- begin field 6bdfbe40-20ce-4fb0-9279-a77c00fd195e --><ul><li><strong>Non-sedating antihistamines are associated with a lower incidence of drowsiness and sedation</strong> (because they penetrate the blood–brain barrier to a lesser extent than sedating antihistamines) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Bernstein, 2014</a>]. However, these adverse effects may still occur.<ul><li>Fexofenadine and loratadine may cause sedation at doses exceeding the recommended doses.</li><li>Cetirizine may cause sedation at recommended doses.</li><li>The sedative effects of antihistamines are enhanced when combined with alcohol.   </li></ul></li><li><strong>Rare adverse effects of antihistamines include</strong> hypotension, palpitation, arrhythmias, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, hypersensitivity reactions (including bronchospasm, angioedema, anaphylaxis, rashes, and photosensitivity reactions), blood disorders, liver dysfunction, nightmares, acute generalized exanthematous pustulosis, arthralgia and angle-closure glaucoma.</li><li>The manufacturer's SPC notes that desloratadine has been associated with an increased incidence of new-onset seizure in patients younger than 20 years of age. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ABPI, 2020</a>]</p><!-- end field 6bdfbe40-20ce-4fb0-9279-a77c00fd195e --><!-- end item bb738227-a078-4184-aa3e-a77c00fd181a -->","subChapters":[]},{"id":"794958fa-1975-54c6-bbd3-c68877ba7c2d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 17d8c813-3ea8-478a-a1e8-a77c00fd311e --><h3>What drug interactions are associated with antihistamines?</h3><!-- end field 17d8c813-3ea8-478a-a1e8-a77c00fd311e -->","summary":"","htmlStringContent":"<!-- begin item 422a6625-d649-493a-ac75-a77c00fd2bf2 --><!-- begin field 0ffb9a02-d017-48fe-ac3a-a77c00fd311e --><ul><li><strong>Drug interactions associated with non-sedating antihistamines include:</strong><ul><li><strong>Ritonavir </strong>— plasma concentration of non-sedating antihistamines possibly increased by ritonavir. </li><li><strong>In addition for fexofenadine:</strong><ul><li><strong>Antacids </strong>— absorption of fexofenadine reduced by antacids. </li><li><strong>Rifampicin </strong>— effects of fexofenadine possibly reduced by rifampicin.</li><li><strong>Ulipristal acetate </strong>— the manufacturer of ulipristal acetate advises that fexofenadine is taken at least 1.5 hours before or after taking ulipristal.</li></ul></li><li><strong>In addition for loratadine:</strong><ul><li><strong>Cimetidine </strong>— the manufacturer of loratadine advises that plasma concentrations are possibly increased by cimetidine.</li><li><strong>Erythromycin </strong>— the manufacturer of loratadine advises that plasma concentrations are possibly increased by erythromycin.</li></ul></li></ul></li><li><strong>Drug interactions associated with all antihistamines include:</strong><ul><li><strong>Alcohol </strong>— increased sedative effect when antihistamines are taken with alcohol (possibly less effect with non-sedating antihistamines).</li><li><strong>Antidepressants (tricyclics, tricyclic-related, and monoamine oxidase inhibitors [MAOIs]):</strong><ul><li>Increased antimuscarinic and sedative effects when antihistamines are taken with tricyclics or MAOIs.</li><li>Possible increased antimuscarinic and sedative effects when antihistamines are taken with tricyclic-related antidepressants.</li></ul></li><li><strong>Antimuscarinics </strong>— increased risk of antimuscarinic adverse effects when antihistamines are taken with antimuscarinic drugs (dosage adjustment may be required).<ul><li>Note that many drugs have antimuscarinic effects. Concurrent use of two or more of such drugs can increase the risk of adverse effects, such as dry mouth, urine retention, and constipation. Concurrent use can also lead to confusion in the elderly. Interactions do not generally apply to inhaled antimuscarinics.</li></ul></li><li><strong>Anxiolytics, hypnotics, and opioids </strong>— increased sedative effect when antihistamines are taken with these groups of drugs.</li><li><strong>Betahistine </strong>— antihistamines theoretically antagonize the effects of betahistine.</li><li><strong>Midodrine </strong>— avoidance of antihistamines advised by manufacturer of midodrine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>] </p><!-- end field 0ffb9a02-d017-48fe-ac3a-a77c00fd311e --><!-- end item 422a6625-d649-493a-ac75-a77c00fd2bf2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}